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INTRODUCTION
The normal cellular isoform of prion protein, des-
ignated PrPC, is a membrane glycoprotein abundantly
expressed in the central nervous system (CNS),
particularly in neurons (1). Its structural counter-
part, the abnormally folded, amyloidogenic isoform,
termed PrPSc, is specifically present in the tissues
affected by prion diseases (1). Prion diseases are a
group of fatal neurodegenerative disorders includ-
ing Creutzfeldt-Jakob disease in humans and scra-
pie and bovine spongiform encephalopathy in ani-
mals (2). The causative agents of the diseases, the
so-called prions, are very different from conventional
pathogens, such as bacteria and viruses (3). Prions
lack a nucleic acid genome (3). According to the
widely accepted protein-only hypothesis, prions are
assumed to consist of PrPSc alone (4). However, the
exact nature of prions still remains controversial.
Here, I will discuss the nature of prions and the roles
of PrP in the pathogenesis of prion diseases.
I will also discuss the normal functions of PrPC
and its antagonistic function to the first identified
PrP-like protein, termed PrPLP/doppel (Dpl) (5).
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pathogenesis of prion diseases. It has been suggested that PrPC might be functionally dis-
turbed by constitutive conversion to PrPSc due to either the resulting depletion of PrPC
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others showed that mice devoid of PrPC (PrP-/-) spontaneously developed abnormal phe-
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of the diseases. However, no neuronal cell death could be detected in PrP-/- mice, indi-
cating that the functional loss of PrPC alone might not be enough to induce neuronal cell
death, one of major pathological hallmarks of prion diseases. Interestingly, it was recently
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toxic in the absence of PrPC, causing Purkinje cell degeneration in the cerebellum of mice.
Although it is not understood if PrPSc could have a neurotoxic potential similar to PrPLP/
Dpl, it is very interesting to speculate that accumulation of PrPSc and the functional dis-
turbance of PrPC, both of which are caused by constitutive conversion, might be required
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PrPLP/Dpl is neurotoxic when ectopically expressed
in neurons, causing Purkinje cell degeneration in
mice, and PrPC antagonizes the neurotoxicity, res-
cuing the mice from neurodegeneration (6, 7). How-
ever, unlike PrPC, PrPLP/Dpl seems to have no po-
tential to convert to a PrPSc-like infectious isoform
(6, 8).
NORMAL AND ABNORMAL ISOFORMS OF
PRP
Normal isoform of PrP
The gene for PrP, designated Prnp , is located on
chromosomes 2 and 20 in human and mouse, re-
spectively (9). Human and hamster Prnp consists of
two exons (9). On the other hand, mouse, sheep,
and rat Prnp contain three exons with exon 3 analo-
gous to exon 2 of human and hamster Prnp . The
protein coding sequence is present in the last sin-
gle exon in all mammals. Prnp is constitutively ex-
pressed in various tissues, with highest expression
in brain, particularly in neurons, and, to a lesser ex-
tent, in others including spleen, kidney, lung, and
heart (10).
Mouse Prnp encodes the precursor protein consist-
ing of 254 amino acids (Fig. 1). The 22 N-terminal
hydrophobic amino acids are removed as a signal
peptide when the nascent precursor protein enters
the endoplasmic reticulum (ER) (Fig. 1). The 23 C-
terminal hydrophobic amino acids are also cleaved
as a glycosylphosphatidylinositol (GPI) -anchor sig-
nal sequence in the ER and, at the same time, a GPI
anchor moiety is attached to the C-terminus of the
serine residue at position 231 (Fig. 1) (1). Then, the
protein is transported to the Golgi apparatus, where
two asparagine residues at positions 181 and 197 un-
dergo N-glycosylation (Fig. 1), and finally to the cell
surface along the secretory pathway. As a result,
mature PrPC, consisting of the amino acid residues
23-231, is expressed as a membrane glycoprotein
anchored to the cell surface via a GPI moiety.
Abnormal isoform of PrP
The abnormal isoform, PrPSc, is specifically pro-
duced within prion infected cells, particularly in neu-
rons. We and others showed that PrPSc failed to be
produced in mice devoid of PrPC (PrP-/-) (11-14),
indicating that PrPC is essential for the generation
of PrPSc. Moreover, it was reported that PrPSc-like
PrP could be generated from PrPC in certain condi-
tions in vitro (15). Therefore, it is thought that PrPSc
is produced from PrPC. However, it remains un-
known whether or not PrPSc is produced from either
mature PrPC or immature unfolded PrP, or both.
PrPSc is identical to PrPC in amino acid sequence.
However, structural analysis of PrPC and PrPSc us-
ing circular dichroism revealed marked differences
in the protein structures of both proteins (Table 1).
PrPC has a lower content of β-sheet strands (3%)
but a higher α-helix content (42%) (16). In contrast,
PrPSc has a higher β-sheet content (43%) (16). It is
therefore postulated that the transition of α-helices
into β-sheet strands within PrP might be a key step
in the generation of PrPSc.
Biochemical and structural properties of PrPs
PrPC and PrPSc possess markedly different bio-
chemical properties from each other, particularly
in detergent solubility and resistance to proteinase
digestion, probably due to the structural differences.
PrPC is highly soluble and easily digested by pro-
teinase K whereas PrPSc readily aggregates to form
Fig. 1. Schematic structures of PrP and PrPLP/Dpl. α and β
indicate α-helix and β-strand, respectively. S-S and Y indicate a
disulfide bond and N-glycosylation, respectively. Arabic figures
represent amino acid positions.
Table 1 Different biochemical and structural properties of PrP isoforms
PrP isoforms





(PrPC) 42% 3% soluble sensitive
Abnormal isoform
(PrPSc) 30% 43% insoluble
relatively
resistant
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amyloid fibers and is relatively resistant to the di-
gestion (Table 1) (1). These different biochemical
properties are useful to distinguish PrPSc from PrPC.
PrPSc remains structurally unresolved due to its
predisposition to form aggregates. In contrast, the
protein structure of PrPC was resolved by nuclear
magnetic resonance (NMR) analysis. According to
NMR analysis, the N-terminal domain of PrPC is
highly flexible and lacks identifiable secondary struc-
ture while the C-terminal domain forms a globular
structure with three α-helices and two short anti-
parallel β-strands (Fig. 1) (17). The second and
third helices are linked by a disulfide bond (Fig. 1)
(17).
The N-terminal domain includes a PrP-specific re-
gion, the so-called octapeptide repeat (OR) region,
in which 8 amino acids are repeated 5 times in tan-
dem (Fig. 1). This region is considered to bind Cu2+
via histidine residues and mediate anti-oxidative ac-
tivities by activating Cu2+-dependent antioxidant en-
zymes such as superoxide dismutase via transfer of
bound Cu2+ to the enzymes (18, 19). However, the
exact function of this region in anti-oxidative activi-
ties remains to be elucidated.
THE FIRST PRP-LIKE PROTEIN (PRPLP/
DPL)
PrPLP/Dpl and PrP
We and others isolated a novel gene, termed Prnd ,
encoding the first PrP-like protein, PrPLP/Dpl, about
16-kb downstream of the PrP gene, Prnp (5, 7).
PrPLP/Dpl is also a GPI-anchored membrane gly-
coprotein (5). Like PrPC, PrPLP/Dpl is first trans-
lated into the precursor protein consisting of 179
amino acids and then undergoes several modifica-
tions, including cleavage of the 23 N-terminal and
25 C-terminal hydrophobic residues as a signal
peptide and a GPI-anchor signal, respectively, N-
glycosylation at two sites, and formation of two di-
sulfide bonds (Fig. 1) (20).
PrPLP/Dpl and PrP share 23% identical amino
acids (5, 7). However, PrPLP/Dpl lacks a region cor-
responding to the N-terminal part of PrPC (5, 7). The
protein structural analysis clearly showed that PrPLP/
Dpl is a structural homologue of the C-terminal globu-
lar domain of PrPC, composed of three α-helices and
two short antiparallel β-strands (Fig. 1) (21).
Normal functions of PrPLP/Dpl
PrPLP/Dpl mRNA is expressed in various tissues
of adult wild-type mice, including the testis, heart,
spleen and skeletal muscle (22). To investigate
the physiological functions of PrPLP/Dpl in mice,
Behrens, et al. produced mice devoid of PrPLP/
Dpl, designated Prnd neo/neo mice (23). Interestingly,
male mutant mice were sterile whereas female mu-
tant mice were fertile. The testes in these mutant
mice were macroscopically normal. However, the
number of spermatozoa and motility of mutant sperm
were significantly decreased. Moreover, the mutant
sperm exhibited abnormal morphologies and im-
paired acrosome function. Consistently, it has been
reported that PrPLP/Dpl is expressed in spermatids
in mice and spermatozoa and Sertoli cells in hu-
mans (23, 24). These results indicate that PrPLP/
Dpl is involved in spermatogenesis.
In contrast to PrPC, PrPLP/Dpl was undetectable
in the brains of adult wild-type mice (22). However,
in neonatal mice, we found substantial expression
of PrPLP/Dpl mRNA in their brains, preferentially
in blood vessel endothelial cells. PrPLP/Dpl mRNA
was already expressed 1 day after birth, peaked by
around 1 week, and then decreased to an undetect-
able level by at least 8 weeks (22). Therefore, such
developmental regulation of PrPLP/Dpl expression
in brain blood vessels suggests that PrPLP/Dpl may
be involved in the development of brain blood ves-
sels and/or blood-brain barrier. However, no patho-
logical abnormalities were detected in the tissues
of Prnd neo/neo mice, including the brain, heart, spleen
and skeletal muscle (23).
PRION RESEARCH IN MICE DEVOID OF
PRP
Protein-only hypothesis and mice devoid of PrP
The protein-only hypothesis postulates that a prion
is constituted of PrPSc alone (25). According to the
hypothesis, a prion or PrPSc interacts with PrPC ex-
pressed on the cell surface and induces changes in
the conformation of the interacting PrPC into that
of PrPSc, resulting in generation of a new PrPSc mole-
cule, or propagation of a prion (Fig. 2). However,
the hypothesis is controversial. If the hypothesis is
true, prions cannot propagate when PrPC is absent.
In contrast, if prions can propagate without PrPC, the
hypothesis is clearly negated. In other words, if
PrP-/- mice can support prion propagation, the hy-
pothesis is wrong, and vise versa.
To investigate validity of the protein-only hypothe-
sis, we generated a line of PrP-/- mice, referred to
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 as Ngsk PrP-/- mice, and intracerebrally inoculated
them with a mouse-adapted Fukuoka-1 prion (14).
Wild-type (PrP+/+) mice developed disease-specific
symptoms at 13812 days and died 14314 days
after inoculation (Table 2). Microscopic examina-
tions of the brains of these diseased mice showed
profound vacuolation and gliosis, both of which are
hallmarks of the pathological changes in prion dis-
eases. In addition, PrPSc was markedly accumulated
and prions were propagated in their brains. In con-
trast, no Ngsk PrP-/- mice showed such specific
symptoms. They were all alive at least by 460 days
after inoculation (Table 2). No disease-specific pa-
thologies were observed in the brains of Ngsk PrP-/-
mice sacrificed 400 days after inoculation. Moreover,
neither accumulation of PrPSc nor prion propagation
could be detected in their brains. Other investiga-
tors also showed similar results using other lines of
PrP-/- mice (11-13). These results indicate that PrPC
is essentially required for prion propagation, and
that prion propagation is linked to accumulation of
PrPSc, strongly supporting the protein-only hypothe-
sis.
Prolonged incubation times and less accumulation
of PrP Sc in mice heterozygous for PrP
We also inoculated Ngsk PrP+/- mice with the
Fukuoka-1 prion (14). Compared with PrP+/+ mice,
Ngsk PrP+/- mice developed the disease with con-
siderably retarded incubation times of 25927 days
and died 26927 days after inoculation (Table 2).
The clinical symptoms and pathological changes in
diseased Ngsk PrP+/- mice were indistinguishable
from those of diseased PrP+/+ mice. However, very
strangely, amounts of PrPSc accumulated in the
brains of terminal PrP+/- mice were only half of
those in terminal PrP+/+ mice (14). These results
indicate that the expression levels of PrPC prior to
infection affect the timing of onset of disease and
the accumulation levels of PrPSc but not the final se-
verity and pathology of disease, and that PrPSc levels
are not correlated with disease progression.
NORMAL FUNCTIONS OF PRP IN NEU-
RONS AND GLIA
Higher brain functions and PrP
Since PrPC is abundantly expressed in pyramidal
neurons of the hippocampus, in which learning and
memory processes are integrated, it has been sug-
gested that PrPC might be involved in learning and
memory processes. Büeler, et al. produced a line
of PrP-/- mice, Zrch I PrP-/-, and subjected them
to behavioral tasks, such as a swimming navigation
test and a Y-maze discrimination test (26). However,
no different performance could be detected in these
tests between the mutant mice and control PrP+/+
mice (26). On the other hand, Nishida, et al. re-
ported poor performance in Ngsk PrP-/- mice us-
ing other behavioral tests, including a water-finding
test and a conditioned passive-avoidance test (27).
Thus, it may be possible that PrPC is involved in cer-
tain types of learning and memory.
Collinge, et al. showed that long-term potentiation
(LTP), a form of synaptic plasticity that is thought
to be important for memory formation, was impaired
in the hippocampal CA1 neurons of Zrch I PrP-/-
mice using electrophysiological studies (28). Similar
results were reported in another line of PrP-/- mice,
Npu PrP-/- mice (29). Therefore, these results seem
to support that PrPC is involved in the processes of
learning and memory. However, other investigators
reported no such electrophysiological abnormalities
in the hippocampus of Zrch I PrP-/- mice (30).
It was also shown that PrPC is involved in the regu-
lation of circadian rhythm (31). In both Zrch I PrP-/-
and Npu PrP-/- mice, much more fragmented sleep
was observed than in PrP+/+ mice (31). Moreover,
Fig. 2. A prion replication model according to the protein-
only hypothesis. A prion is constituted of the abnormal isofrom
of PrP, PrPSc, interacts with the normal isoform of PrP, PrPC,
and induces the conformational changes of the interacting PrPC
to produce a new molecule of PrPSc or a prion. The newly pro-
duced PrPSc or prion also converts another PrPC into PrPSc or
prion in the same way.
Table 2 Ngsk PrP-/- mice were resistant to prion disease.
Mouse genotype Incubation time (meanSD days) Survival time (meanSD days)
Wild-type 13812 14314
Ngsk PrP+/- 25927 26927
Ngsk PrP-/- 460 460
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 the mutant mice exhibited a much longer activity
period of 23.9 h under constant darkness, compared
to 23.3 h in PrP+/+ mice (31).
Axonal myelination and PrP
We found many vacuoles in the spinal cord and
peripheral nervous system of Ngsk PrP-/- and Zrch
I PrP-/- mice (32). Most of the vacuoles were sur-
rounded by an enlarged myelin sheath, but in some
cases splits within a myelin sheath formed vacuoles
(32). In addition, large myelinated fibers were re-
duced in number and remaining axons were thinly
myelinated (32). Subsequently, we could rescue
Ngsk PrP-/- mice from the demyelination by trans-
genically expressing mouse PrPC (32). These results
indicate that PrPC is involved in the organization of
the myelin sheath.
PrPC is expressed on the surface of oligodendro-
cytes and Schwann cells (33, 34), both of which form
myelin sheaths in the CNS and the peripheral nerv-
ous system, respectively. It is therefore conceivable
that PrPC functions as an adhesion molecule within
a myelin sheath and/or between a myelin sheath
and an axon to form a tightly compacted myelin
sheath. This might be consistent with the result that
some vacuoles were formed due to splits within mye-
lin sheaths. It is alternatively possible that PrPC
could be a trophic factor for these glial cells.
PRP AND PRPLP/DPL IN NEURODEGEN-
ERATION
Purkinje cell degeneration among different lines of
mice devoid of PrP
No neuropathological abnormalities were reported
in Zrch I PrP-/- and Npu PrP-/- mice (26, 35). How-
ever, very strangely, we noticed that Ngsk PrP-/-
mice showed ataxic gait around 70 weeks after birth
(36). In these ataxic mice, cerebellar Purkinje cells
were dramatically decreased in number due to their
degeneration and the molecular layer also became
very thin, probably due to the loss of the dendritic
trees of Purkinje cells (Fig. 3) (36). In contrast, no
Purkinje cell degeneration could be detected in
younger Ngsk PrP-/- mice and old PrP+/+ and Ngsk
PrP+/- mice (36). We also confirmed that the ataxia
and Purkinje cell degeneration in Ngsk PrP-/- mice
could be successfully rescued by introduction of
the transgene encoding PrPC (Fig. 3) (32). Similar
cerebellar degeneration was subsequently reported
in other lines of PrP-/- mice, such as Rcm0 PrP-/-
and Zrch II PrP-/- mice (5, 37). Taken together,
these results indicated that the functional loss of
PrPC is responsible for Purkinje cell degeneration,
although it remained unknown why the neurode-
generation was discrepant among different lines of
PrP-/- mice.
In Zrch I PrP-/- mice, a part of the PrP open read-
ing frame (ORF) was replaced with the neomycin
phosphotransferase (neo) gene (Fig. 4) (26). In Npu
PrP-/- mice, the neo gene was simply inserted into
a unique site in the PrP-coding sequence (Fig. 4)
(35). In contrast, in the ataxic lines of Ngsk PrP-/-,
Rcm0 PrP-/-, and Zrch II PrP-/- mice, the entire
ORF was completely deleted (Fig. 4) (5, 36, 37). It
was therefore conceivable that in non-ataxic lines
of Zrch I PrP-/- and Npu PrP-/- mice, some as-
pects of the normal function of PrPC might remain
intact because of incomplete disruption of the PrP
allele. Consistently, it was reported that a fused
mRNA consisting of the neo and the residual Prnp
sequences was produced in their brains (26). Al-
ternatively, it might be possible that the loss of PrPC
alone may not be enough to induce Purkinje cell de-
generation, and that other factor(s), which are spe-
cifically associated with the ataxic lines of PrP-/-
mice, together with the loss of PrPC, are involved
in the neurodegeneration.
Ectopic expression of PrPLP/Dpl associated with
Purkinje cell degeneration
We found that, in the brains of Ngsk PrP-/- mice
but not in Zrch I PrP-/- and PrP+/+ mice, the PrPLP/
Dpl-coding exons were ectopically expressed as chi-
meric mRNAs with the residual non-coding Prnp
exons 1 and 2 due to an abnormal intergenic splic-
ing taking place between Prnp and Prnd (7). In
Ngsk PrP-/- mice, due to lack of the 3’ part of in-
tron 2 including a splice acceptor, the pre-mRNA
transcribed from the residual Prnp promoter could
not efficiently undergo cleavage/polyadenylation
at the end of Prnp (Fig. 5B). The unsuccessfully
cleaved pre-mRNA was then elongated until the last
Fig. 3. Purkinje cell degeneration in Ngsk PrP-/- mice and
Purkinje cells rescued in Ngsk PrP-/- mice transgenic for PrPC.
Purkinje cells are immunohistochemically stained using anti-
calbindin antibodies and can be observed as brownish dots.
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Fig. 4. Targeted PrP alleles among different lines of PrP-/- mice. In Ngsk PrP-/- mice, a 2.1-kb genomic DNA segment including
0.9-kb of intron 2, 10-bp of 5’ untranslated region (UTR) of exon 3, the entire PrP ORF, and 0.45-kb of 3’ UTR is replaced by the neo
gene under the control of the mouse phosphoglycerate kinase (PGK) promoter. Rcm0 PrP-/- mice were generated by a similar targeting
strategy utilized in Ngsk PrP-/- mice. The hypoxanthine phosphoribosyltransferase gene under control of the PGK promoter was used
in Rcm0 PrP-/- mice as a selectable marker. In Zrch II PrP-/- mice, 0.27-kb of intron 2, the entire exon 3, and 0.6-kb of the 3’ flank-
ing DNA segment were targeted by a specific 34-bp loxP sequence. In these lines of PrP-/- mice, the entire PrP ORF is completely
deleted. In contrast, Zrch I PrP-/- mice were generated by replacement of PrP codons 4-187 among a total of 254 codons with the
neo gene under the control of the herpes simplex virus thymidine kinase promoter. Npu PrP-/- mice contain the disrupted Prnp al-
leles, in which the neo gene under the control of the mouse metalothioneine promoter was simply inserted into a unique Knp I site
in the PrP-coding sequence.
Fig. 5. Mechanism for the generation of PrPLP/Dpl-encoding chimeric mRNAs in Ngsk PrP-/- mice. In wild-type mice, the PrP
pre-mRNA is normally cleaved and polyadenylated at the last exon of the Prnp (A). However, in Ngsk PrP-/- mice, due to lack of the
3’ part of intron 2, the pre-mRNA transcribed from the Prnp promoter could not efficiently undergo cleavage/polyadenylation at the
last exon of Prnp , being further elongated until the last exon of Prnd , and subjected to intergenic splicing between the residual Prnp
exons 1/2 and the PrPLP/Dpl-coding exon (B). As a result, PrPLP/Dpl became abnormally expressed under the control of the Prnp
promoter, leading to the ectopic expression of PrPLP/Dpl in the brains of ataxic lines of PrP-/- mice.
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exon of Prnd and subjected to intergenic splicing
between the residual Prnp exon 2 and the PrPLP/
Dpl-coding exon, producing chimeric mRNAs con-
sisting of the Prnp exons 1 and 2 and the PrPLP/Dpl-
coding exons (Fig. 5B). As a result, Prnd became
abnormally regulated under the control of the Prnp
promoter in Ngsk PrP-/- mice and PrPLP/Dpl was
ectopically expressed in the brains, especially in
neurons and glial cells where the promoter is very
active (7). Similar ectopic expression of PrPLP/
Dpl was subsequently reported in other ataxic lines
of PrP-/- mice, Rcm0 PrP-/- and Zrch II PrP-/-
mice (5, 37). Taken together, these results indi-
cate that the ectopic expression of PrPLP/Dpl in the
absence of PrPC might be responsible for Purkinje
cell degeneration in the ataxic lines of PrP-/- mice.
PrPLP/Dpl in the absence of PrP causes Purkinje
cell degeneration
To investigate the possibility that ectopic expres-
sion of PrPLP/Dpl in the absence of PrPC could
cause the Purkinje cell degeneration, we generated
transgenic mice, referred to as tg(N-PrPLP/Dpl)
mice, in which PrPLP/Dpl was specifically expressed
in nearly all neurons including Purkinje cells under
the control of the neuron-specific enolase promoter,
and subsequently crossed them with the non-ataxic
line of Zrch I PrP-/- mice (38). Tg(N-PrPLP/Dpl)
32 mice expressed PrPLP/Dpl in the cerebellum
at a level about 1-2 times more than that of Ngsk
PrP-/- mice, developing ataxia at 5815 days on the
Zrch I PrP-/- background (Table 3). Purkinje cells
were markedly decreased in number due to the de-
generation in these ataxic tg mice. In contrast, nei-
ther ataxia nor Purkinje cell degeneration could be
detected in the tg mice carrying the PrP+/+ back-
ground (Table 3). Another tg(N-PrPLP/Dpl)25
mouse line, in which PrPLP/Dpl was expressed in
the cerebellum at a level less than a quarter that of
Ngsk PrP-/- mice, also developed ataxia and Purk-
inje cell degeneration at 35952 days on the Zrch
I PrP-/- background but not on the PrP+/+ back-
ground (Table 3). These results clearly showed that
the ectopic expression of PrPLP/Dpl is neurotoxic
in the absence of PrPC, causing the Purkinje cell de-
generation, and that the neurotoxicity of PrPLP/Dpl
is antagonized by PrPC.
We also produced another type of tg mice, tg(P-
PrPLP/Dpl) mice (38). In these tg mice, the ex-
pression of PrPLP/Dpl was specifically targeted to
Purkinje cells under the control of the Purkinje cell
protein-2 promoter (38). Like tg(N-PrPLP/Dpl)
mice, tg(P-PrPLP/Dpl) mice developed ataxia and
Purkinje cell degeneration on the Zrch I PrP-/- back-
ground but not on the PrP+/+ background (38).
Tg(P-PrPLP/Dpl)26 and 27 mice showed ataxia at
26828 and 16713 days after birth, respectively,
on the Zrch I PrP-/- background (Table 3). These
results clearly indicate that PrPLP/Dpl ectopically
expressed on Purkinje cells is itself neurotoxic to
the cells.
Stoichiometrical antagonism between PrP and PrPLP/
Dpl in neurodegeneration
The times to the onset of ataxia in tg(N-PrPLP/
Dpl) mice were inversely correlated with the ex-
pression levels of PrPLP/Dpl (38). Tg(N-PrPLP/
Dpl)32 mice expressed more PrPLP/Dpl in the cere-
bellum and developed the ataxia earlier than tg(N-
PrPLP/Dpl)25 mice (Table 3). In contrast, the lev-
els of PrPC were correlated with the times of the on-
set. Tg(N-PrPLP/Dpl)32 and 25 mice showed sig-
nificantly retarded onset of the ataxia on the Zrch I
PrP+/- background, compared with the Zrch I PrP
-/- background (Table 3). Thus, these results indi-
cate that PrPLP/Dpl and PrPC stoichiometrically an-
tagonize each other to induce Purkinje cell degen-
eration.
N-terminal domain of PrP antagonistic for PrPLP/
Dpl
PrPC possesses the OR region-containing N-terminal
domain whereas PrPLP/Dpl lacks the correspond-
ing domain. It is therefore conceivable that the N-
terminal domain might be important for PrPC to
antagonize against the PrPLP/Dpl neurotoxcity.
To investigate the possibility, we introduced PrP
with a deletion of the N-terminal residues 23-88
Table 3 PrPLP/Dpl stoichiometrically antagonizes PrPC to induce ataxia
Tg lines
Onset of ataxia on different genetic backgrounds (meanSD days)
Zrch I PrP-/- Zrch I PrP+/- Wild-type
Tg(N-PrPLP/Dpl)
25 35952 49586 600
32 5815 25948 600
Tg(P-PrPLP/Dpl)
26 26828 46381 600
27 16713 391108 600
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into Ngsk PrP-/- mice (39). As expected, the dele-
tion mutant PrP failed to rescue Ngsk PrP-/- mice
from ataxia and Purkinje cell degeneration (39).
Ngsk PrP-/- mice expressing the deletion mutant
developed ataxia and Purkinje cell degeneration
on a time course identical to that of non-transgenic
Ngsk PrP-/- mice (39). These clearly indicate that
the N-terminal residues 23-88 are important for PrPC
to antagonize the neurotoxicity of PrPLP/Dpl. The
N-terminal residues 23-88 include most of the OR
region. Thus, it is suggested that this OR region
could be important for PrPC to protect Purkinje cells
from PrPLP/Dpl-induced degeneration, although it
remains to be investigated which region in the de-
leted N-terminal domain could be essential for the
neuroprotection of PrPC against PrPLP/Dpl.
We also introduced PrP carrying a familial prion
disease-associated mutation (E199K) into Ngsk
PrP-/- mice (39). Interestingly, these mice devel-
oped no ataxia and Purkinje cell degeneration (39),
showing that the mutant PrP was fully functional
for antagonizing the PrPLP/Dpl-induced neurotox-
icity, suggesting that other disease-associated mu-
tant PrPs are also functionally competent.
PRP AND PRPLP/DPL IN ISCHEMIC NEU-
RONAL CELL DEATH
To assess whether PrPC and PrPLP/Dpl could be
involved in other types of neuronal cell death, we
subjected Zrch I PrP-/- and Ngsk PrP-/- mice to
transient forebrain ischemia (40). Interestingly, male
Zrch I PrP-/- mice were very susceptible to the ische-
mia compared to control PrP+/+ mice, developing
marked apoptosis in the hippocampal CA1 region
(40). McLennan, et al. also reported that perma-
nent occlusion of the middle cerebral artery in-
creased the infarction volume in male Npu PrP-/-
mice without no ectopic expression of PrPLP/Dpl
in neurons (41). However, no apoptotic cell death
could be detected in the CA 1 of female Zrch I PrP-/-
mice (40). Taken together, these results indicate
that PrPC is involved in neuroprotection against
brain ischemia, and that the neuroprotective func-
tion of PrPC is masked by female-specific neuropro-
tective factor(s).
We also showed that, in contrast to Zrch I PrP-/-
mice, both male and female Ngsk PrP-/- mice ex-
hibited severe ischemic damage to CA1 neurons
(40). Since Ngsk PrP-/- mice ectopically express
PrPLP/Dpl in neurons, it is therefore conceivable
that PrPLP/Dpl might counteract the female-specific
neuroprotective function, thereby increasing the
susceptibility of PrPC-deficient neurons to ischemic
insults.
ROLES OF PRP AND PRPLP/DPL IN NEU-
RODEGENERATION
Neurotoxic PrPs
PrPLP/Dpl is a homologue of the C-terminal part
of PrPC. Interestingly, it was shown that the N-
terminally truncated PrPs, PrP32-121 and PrP
32-134, induced ataxia and cerebellar degeneration
characterized by marked granule cell death in Zrch
I PrP-/- mice and the neurotoxicity of these trun-
cated PrPs was antagonized by the expression of
full-length PrPC (42). No Purkinje cell degeneration
was observed in these mice because the truncated
PrPs were not expressed in Purkinje cells of these
mice due to the limited activity of the promoter used
(42). Consistently, it was demonstrated that ataxia
and Purkinje cell loss could be induced in Zrch I
PrP-/- mice when PrP32-134 was targeted to Purk-
inje cells (43). PrP32-121 and PrP32-134 encom-
pass the homologous C-terminal part of PrPC to
PrPLP/Dpl. It is therefore very likely that PrPLP/
Dpl and the truncated PrPs might use the same or
a very similar molecular mechanism to execute the
neurotoxicity.
Cis- and trans-neuroprotective function of PrP
against PrPLP/Dpl
In contrast to neurotoxic PrP32-121 and PrP
32-134, it was shown that PrP23-88 was not neu-
rotoxic, causing no Purkinje cell degeneration in
Zrch I PrP-/- mice (39), suggesting that the neuro-
toxicity of the C-terminal domain of PrPC is blocked
by a cis-element(s) present in the region between the
residues 89 and 121. This region, overlapping with
the central hydrophobic part, is reported to com-
prise part of the binding sites for the heat shock
protein, stress-inducible protein 1, and the extra-
cellular matrix constituent glycosaminoglycans (44,
45). It is therefore possible that interaction of PrPC
with these molecules might be involved in the cis-
inhibition of the neurotoxicity of the C-terminal
domain of PrPC. In contrast, PrPLP/Dpl and the
truncated PrPs are unable to interact with these
molecules, therefore acting as neurotoxic proteins.
PrPC also neutralizes the neurotoxicity of PrPLP/
Dpl and the truncated PrPs in trans, rescuing from
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the Purkinje cell degeneration. Interestingly, we
showed that PrP23-88 has no such trans-neuropro-
tective activity, unable to antagonize against PrPLP/
Dpl (39). It is therefore suggested that N-terminal
residues 23-88 are involved in the trans-neuropro-
tection of PrPC against PrPLP/Dpl and probably the
truncated PrPs as well.
Antagonistic signals of PrP and PrPLP/Dpl in
neuronal cell death
Kuwahara, et al. previously reported that hip-
pocampal neuronal cells from PrP-/- mice easily
undergo apoptosis after withdrawal of serum, which
can be prevented by either re-introduction of PrPC or
by expressing the anti-apoptotic protein, Bcl-2 (46).
Bounhar, et al. also showed that PrPC protected hu-
man primary neurons from the apoptosis induced
by the pro-apoptotic protein Bax (47). It is therefore
suggested that PrPC might be an anti-apoptotic pro-
tein while PrPLP/Dpl might be pro-apoptotic.
It was shown that the primary cultured cerebel-
lar neurons from non-ataxic Npu PrP-/- mice were
more sensitive to oxidative stress than those from
PrP+/+ mice (19), indicating that PrPC might be
involved in mitigation of oxidative stress. Interest-
ingly, Wong, et al. showed that oxidative stress was
much more elevated in the brains of ataxic Rcm0
PrP-/- mice than in those of non-ataxic Npu PrP-/-
mice (48). It is therefore suggested that, in contrast
to PrPC, PrPLP/Dpl aggravates oxidative stress. Oxi-
dative stress is associated with overproduction of
radical oxygens, such as superoxide and nitric oxide
(NO). Interestingly, it was shown that enzymatic
activity of superoxide dismutase, a superoxide-
detoxifying enzyme, was significantly decreased in
PrP-/- mice (18). Moreover, it was reported that
recombinant PrPLP/Dpl was toxic to the cultured
cerebellar neurons of non-ataxic Zrch I PrP-/- mice
and that this PrPLP/Dpl-neurotoxicity could be pre-
vented by L-N -acetyl methyl ester, a pharmacologi-
cal inhibitor of NO synthases (49). It is therefore
possible that PrPLP/Dpl might aggravate oxidative
stress by overproducing NO and superoxide, thereby
causing Purkinje cell death, and that PrPC could
detoxify it, preventing PrPLP/Dpl-induced neurode-
generation.
It was previously shown that, in Zrch I PrP-/-
mice, Ca2+-activated K+ currents in hippocampal py-
ramidal neurons were abnormal and intracellular Ca2+
contents in cerebellar granule cells were altered (50).
Moreover, we showed that the T- and L-type Ca2+-
antagonist, flunarizine, significantly reduced the
PrPLP/Dpl-aggravated ischemic neuronal apoptosis
in Ngsk PrP-/- mice (40). Since excess of intracel-
lular Ca2+ has been shown to be toxic to neurons
(51), it is alternatively possible that PrPC could re-
duce the intracellular Ca2+ load in neurons, thereby
being neuroprotective, and that, in contrast, PrPLP/
Dpl increases the intracellular Ca2+ load in neurons,
thereby enhancing the susceptibility of neurons to
apoptosis.
A proposed model of antagonistic interaction be-
tween PrP and PrPLP/Dpl
Weissmann and colleagues have proposed an in-
teresting hypothesis, in which two conjectural mole-
cules, protein π, which is another PrP-like protein,
and a cognate ligand for PrPC, are introduced (42,
52). In normal mice, PrPC binds its cognate ligand to
elicit a neuroprotective signal, thereby Purkinje cells
are able to survive. But, in ataxic lines of PrP-/- mice,
PrPLP/Dpl or the neurotoxic truncated PrPs com-
pete with PrPC for the ligand and blocks the signal,
resulting in Purkinje cell degeneration. In non-ataxic
lines of PrP-/- mice, instead of PrPC, the protein π
could elicit the same neuroprotective signal via bind-
ing to the ligand, thereby causing no Purkinje cell
degeneration. However, this hypothesis can be veri-
fied only when the putative molecules are identified.
FINDINGS IN PRP-NULL MICE AND PATHO-
GENESIS OF PRION DISEASES
The molecular pathogenesis of prion diseases re-
mains elusive. Since PrP-/- mice were resistant to
these diseases (11-14), it is considered that the con-
formational conversion of PrPC to PrPSc plays an es-
sential role in the pathogenesis of the diseases. How-
ever, the exact nature of this role has not been fully
understood. PrPSc is markedly accumulated in in-
fected brains due to constitutive conversion. Forloni,
et al. showed that an amyloidogenic PrP peptide
(PrP106-126) was highly toxic to primary cultured
neurons (53). It is therefore conceivable that PrPSc
might itself be neurotoxic. In contrast, Yokoyama,
et al. showed that the PrPC-specific immunoreactiv-
ity was decreased in the brain regions where PrPSc
had accumulated in experimentally infected mice
(54), indicating that PrPC is reduced in the infected
neurons due to conversion. It is therefore alterna-
tively possible that PrPC might be functionally dis-
turbed due to its marked reduction, thereby result-
ing in the nerodegeneration. Or, both the accumu-
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lation of PrPSc and the functional loss of PrPC might
be required for the neuronal cell death.
PrP-/- mice without ectopic expression of PrPLP/
Dpl exhibited neurological abnormalities, including
impairment of LTP, alteration in sleep and circadian
rhythm, as well as demyelination in the spinal cord
and peripheral nervous system (28, 31, 32). LTP is
a form of synaptic plasticity that is thought to un-
derlie memory formation. Memory loss or demen-
tia is a common symptom in prion diseases (55).
Alteration in sleep and circadian rhythms is also a
symptom characteristic for the inherited human prion
disease, fetal familial insomnia (55). Moreover, de-
myelinating peripheral neuropathy has been reported
in some cases of inherited prion disease (56, 57).
Taken together, these results strongly support that
the functional loss of PrPC is involved in these patho-
genic changes in the diseases. However, no neuro-
nal cell degeneration could be detected in mice de-
void of PrPC alone, indicating that loss of PrPC alone
might not be enough to induce neuronal cell death
or that other neurotoxic mechanisms might asso-
ciate with neuronal cell death in prion diseases.
Interestingly, the ectopic expression of PrPLP/
Dpl, PrP32-121, or PrP32-134 in the absence of
PrPC caused degeneration of Purkinje cells and gran-
ule cells (6, 38, 42). Purkinje cells and granule cells
are markedly degenerative in human prion diseases
(55). It is therefore conceivable that PrPLP/Dpl
and the truncated PrPs might be involved in the
pathogenesis of the diseases. However, PrPLP/Dpl
itself is unlikely to be involved in the pathogenesis
of prion diseases because PrPLP/Dpl could not be
detected in the brains affected by experimental prion
diseases (6, 8). Instead, PrPSc is markedly accumu-
lated and its fragmented C-terminal products are
often observed in the affected brains (58). It is there-
fore very interesting to speculate that PrPSc or its
fragmented products possess a neurotoxic poten-
tial equivalent to that of PrPLP/Dpl, PrP32-121,
or PrP32-134. Thus, elucidation of the molecular
mechanism for the Purkinje cell degeneration in
ataxic lines of PrP-/- mice might be useful for un-
derstanding of the molecular pathogenesis of prion
diseases.
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